Notification of half year results date

Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the global pharmaceutical and services company, will announce its half year results for the six months ended 31 December 2018 on Wednesday, 27 February 2019.

A group analyst briefing will be held at 9:30am on Wednesday, 27 February 2019 at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ.

Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email clinigen@instinctif.com to register.

-Ends-

Contact Details

Clinigen Group plc

Shaun Chilton, Group Chief Executive Officer
Martin Abell, Group Chief Financial Officer
Matt Parrish, Head of Investor Relations
Tel: +44 (0) 1283 495010

Numis Securities Limited
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)
Tel: +44 (0) 20 7260 1000

RBC Capital Markets – Joint Broker
Marcus Jackson / Elliot Thomas
Tel: +44 (0) 20 7653 4000

Instinctif Partners 
Adrian Duffield / Melanie Toyne-Sewell
Email: clinigen@instinctif.com
Tel: +44 (0) 20 7457 2020

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.

 

For more information on Clinigen, please visit www.clinigengroup.com